Stem Cell Transplant and Cellular Symposium 2026S CME

Add to Calendar Stem Cell Transplant and Cellular Symposium 2026S CME 8/29/2026 7:30:00 AM 8/29/2026 4:00:00 PM America/Chicago For More Details: https://vumc.cloud-cme.com/course/courseoverview?EID=124718 Description: The course will be offered on August 29, 2026 from 7:30 am to 4:00 pm at the Loews Vanderbilt Hotel, 2100 West End Avenue in Nashville, TN. The course is designed to help primary care clinicians and community oncologist understand the potential of emerging applications of novel therapies in cellular therapy and bone marrow stem cell transplant for their patients with hematologic disorders and solid tum... false MM/DD/YYYY


Saturday, August 29, 2026, 7:30 AM - 4:00 PM, Nashville, TN


Specialties - Medicine, Nursing, Pathology, Microbiology and Immunology, Pediatrics, Pharmacy, Radiation Oncology


AMA PRA Category 1 Credits™ (8.50 hours), Non-Physician Attendance (8.50 hours)


The course will be offered on August 29, 2026 from 7:30 am to 4:00 pm at the Loews Vanderbilt Hotel, 2100 West End Avenue in Nashville, TN. The course is designed to help primary care clinicians and community oncologist understand the potential of emerging applications of novel therapies in cellular therapy and bone marrow stem cell transplant for their patients with hematologic disorders and solid tumors. After listening to lectures and case discussions, primary care clinicians and community oncologist should be able to describe and discuss current stem therapy options for patients with hematological disorders or solid tumors, current CAR T-cell therapy indications, procedures, outcomes, and limitations.


Objectives
After participating in this educational activity, you should be able to:

  1. Discuss the latest FDA-approved and emerging indications for CAR T-cell therapy and hematopoietic stem cell transplantation (HCT) across hematologic malignancies and solid tumors
  2. Understand the presentation patterns, onset, and management strategies for unique adverse events, specifically Cytokine Release Syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
  3. Describe comprehensive multidisciplinary and supportive care protocols required for patients before, during, and after cellular therapy infusions


Vanderbilt University Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vanderbilt University Medical Center designates this live activity for a maximum 8.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.